

# Modeling Drug Mechanism Knowledge Using Evidence and Truth Maintenance

Richard Boyce, *Member, IEEE*, Carol Collins, John Horn, and Ira Kalet

**Abstract**—To protect the safety of patients, it is vital that researchers find methods for representing drug mechanism knowledge that support making clinically relevant drug-drug interaction (DDI) predictions. Our research aims to identify the challenges of representing and reasoning with drug mechanism knowledge and to evaluate potential informatics solutions to these challenges through the process of developing a knowledge-based system capable of predicting clinically relevant DDIs that occur via metabolic mechanisms. In previous work, we designed a simple, rule-based, model of metabolic inhibition and induction and applied it to a database containing assertions about 267 drugs. This pilot system taught us that drug mechanism knowledge is often dynamic, missing, or uncertain. In this paper, we propose methods to address these properties of mechanism knowledge and describe a new prototype system, the Drug Interaction Knowledge-base (DIKB), that implements our proposed methods so we can explore their strengths and limitations. A novel feature of the DIKB is its use of a Truth Maintenance System to link changes in the evidence support for assertions about drug properties to the set of drug-drug interactions and non-interactions the system predicts.

**Index Terms**—drug interactions, drug mechanisms, Truth Maintenance Systems, knowledge representation

## I. INTRODUCTION

**M**ECHANISM-BASED drug-drug interaction (DDI) prediction is important during drug development to predict interactions between a potential new drug and drugs currently on the market. Systems that model drug mechanisms are being applied in this “pre-market” setting to identify optimal drug candidates, predict drug properties, assess the efficacy and safety of new drugs and estimate dose to concentration relationships [1]. Pre-market modeling efforts are geared towards identifying interactions between a new drug and drugs with which it might be co-administered early on, before much time and money is invested [2], [3]. The predictions made using drug-mechanisms can indicate that two drugs might interact via a mechanism but generally offer only a qualitative estimate of the magnitude of the interaction. Scientists can use

This version submitted on October 18, 2005; revised October 31, 2006. This work supported in part by NIH grant T15 LM07442 from the National Library of Medicine. Ira Kalet gratefully acknowledges support from NIH grant LM008788 from the National Library of Medicine.

All authors are with the University of Washington.

Richard Boyce and Ira Kalet are with the program of Biomedical and Health Informatics 1959 NE Pacific St, HSC I-264, Seattle, WA 98195-7240 (e-mail: boycer@u.washington.edu; ikalet@u.washington.edu)

Carol Collins is with the Metabolism and Transport Database, Department of Pharmaceutics. (e-mail: carolc3@u.washington.edu)

John Horn is with the Department of Pharmacy (e-mail: jrhorn@u.washington.edu)

these qualitative predictions to select the set of clinical trials necessary to establish a new drug’s safety profile [4].

An important fact is that the same knowledge that is useful for predicting DDIs in the pre-market setting can help clinicians in the post-market setting assess the possibility of a DDI occurring between two drugs that have never been studied together in clinical trials [5]. In spite of this fact, and the position of the FDA that all relevant information on mechanisms from pre-market investigations be included in drug product labeling [6], little research has been done on how to best represent, utilize, and maintain pharmacokinetic and pharmacodynamic drug mechanism knowledge for the purpose of making DDI predictions in the post-market setting. Our research is beginning to fill this knowledge gap through the process of developing a knowledge-based system capable of predicting clinically relevant DDIs that occur via metabolic mechanisms. The purpose of developing the system is to identify the challenges of representing and reasoning with post-market drug mechanism knowledge and to evaluate potential informatics solutions to these challenges.

In the next section we describe our previous research in mechanisms-based DDI prediction and the specific challenges to representing drug mechanism knowledge this early work helped us identify. We then propose informatics methods to address each challenge while discussing related work. Then follows a detailed description of a new prototype system, the Drug Interaction Knowledge-base, that implements our proposed methods and employs a novel use of a non-monotonic logic system called a Truth Maintenance System to link changes in the evidence support for assertions about drug properties to the set of drug-drug interactions and non-interactions the system predicts. Finally, we conclude by relating some early research findings and proposing future research aims.

## II. PREVIOUS WORK

Previously, in order to better understand the issues of formally representing DDI knowledge, we constructed a First Order Logic model of the mechanisms underlying DDIs from the lectures and class notes of a graduate class on drug-interactions. Several categories of DDIs were covered in the class including DDIs involving changes to liver or kidney function, gastro-intestinal motility and absorption, transport protein function, and metabolism. We selected for further experimentation rules from this representation that model the jointly sufficient conditions for metabolic inhibition or induction DDIs. These rules were interesting because a large

number of DDIs can be explained by metabolic mechanisms, especially for drugs metabolized by the Cytochrome-P450 (CYP450) enzymes, and considerable research data exists on the metabolic properties of many drugs.

We constructed a small database containing the necessary drug facts for inference with the selected rules. Facts on the important metabolic enzymes for 267 currently prescribed drugs were input into the knowledge-base (KB) from two references [7], [8]. Our methods for combining information from these two references are described in [9]. Since our system could provide no quantitative estimates of its DDI predictions we modified the rules to apply only to drugs with a *narrow-therapeutic index*, meaning that there is a small gap between the toxic dose of a drug and the dose at which the drug is ineffective. Any interaction involving a narrow-therapeutic index (NTI) drug could potentially result in harm to a patient, so this change ensured that predictions would be clinically relevant.

We applied the selected rules by performing two queries against the drug KB for any drugs that inhibit or induce the primary clearance enzyme of another NTI drug whose clearance is primarily metabolism. The queries returned a total of 90 predicted DDIs out of 71,022 possible pairwise combinations. We then checked the 90 predictions against four online drug reference databases.<sup>1</sup> A predicted drug-drug interaction was considered clinically viable if it was reported in any of the four sources.

TABLE I

PREDICTED INHIBITION INTERACTIONS FROM OUR PILOT DRUG-DRUG INTERACTION KNOWLEDGE-BASE NOT DOCUMENTED IN ANY OF FOUR ONLINE REFERENCES. IN EACH ROW, THE PRECIPITANT DRUG INHIBITS THE PRIMARY CLEARANCE ENZYME (PCE) OF THE OBJECT DRUG BASED ON INFORMATION IN OUR PILOT SYSTEM.

<i>Precipitant</i>	<i>PCE</i>	<i>Object</i>
amiodarone	CYP2C9	phenobarbital
disulfiram	CYP2C9	phenobarbital
fluorouracil	CYP2C9	phenobarbital
fluconazole	CYP2C9	phenobarbital
gemfibrozil	CYP3A4	carbamazepine
gemfibrozil	CYP2C9	phenobarbital
gemfibrozil	CYP2C9	phenytoin
leflunomide	CYP2C9	phenobarbital
miconazole	CYP3A4	carbamazepine
sulfamethizole	CYP2C9	phenobarbital
sulfamethoxazole	CYP2C9	phenobarbital
sulfinpyrazone	CYP2C9	phenobarbital
sulphaphenazole	CYP2C9	phenobarbital
zafirlukast	CYP3A4	carbamazepine
zafirlukast	CYP2C9	phenytoin
zafirlukast	CYP2C9	phenobarbital

Seventy-four of our ninety predicted DDIs were found in at least one drug reference while sixteen could not be found in any online reference (see Table I). We recognized that the sixteen predicted interactions not found in any drug reference were not necessarily false predictions. It is not possible to test every possible drug combination in a clinical trial and

<sup>1</sup>First Data Bank's Micromedex, WebMD's Medscape, Discovery health.discovery.com, and Cerner Multum's Drugs.com.

the effects of drug interactions can be very hard to recognize so that some drug interactions escape notice in the scientific literature until years after a drug comes to market. The pilot system's predictions were based on pharmacokinetic principles that are considered valid indicators of potential interactions in FDA guidelines [6]. The clinical relevance of these predictions was based on the assumption that any change in the exposure of a patient to a NTI drug is of clinical interest. Thus, it is possible that some of these predictions are valid interactions that have not been studied.

We looked carefully at the evidence behind each fact in our database that supported any of the sixteen novel interaction predictions and found that several facts in the drug KB had varying degrees of support from the scientific literature. For example, we found *in vitro* evidence for zafirlukast inhibition of CYP3A4 and citation of a single study where patients experienced no change in their exposure to a known CYP3A4 substrate when given zafirlukast [10]. Given this evidence, the clinical relevance of zafirlukast inhibition of CYP3A4 is still unknown because 1) even with very solid *in vitro* evidence, a pharmacokinetic drug property might not have much clinical relevance at the doses in which drugs are prescribed [11], [12] and 2) the substrate mentioned in the above study is not a probe substrate for CYP3A4. The evidence that gemfibrozil inhibits CYP2C9 was more substantial, including a *in vitro* study [13] and case report [14] showing a significant increase in the exposure of a patient to warfarin, a drug primarily cleared from the body by CYP2C9 metabolism, when the patient was given gemfibrozil. Thus, based on evidence, the clinical relevance of interaction prediction involving zafirlukast inhibition of CYP3A4 is less certain than the two predictions involving gemfibrozil inhibition of CYP2C9 (Table I).

Examination of the evidence for other drug properties in this pilot system revealed that important drug mechanism knowledge is sometimes missing. For example, all 11 of the interactions involving phenobarbital in Table I are predicted to occur by inhibition of phenobarbital's primary metabolic clearance pathway which we listed as CYP2C9 based on one source [8]. We could only indirectly support the hypothesis that phenobarbital is a CYP2C9 substrate with two studies from the early 1980s that identified an apparent metabolic interaction between sodium valproate and phenobarbital [15], [16] and an *in vitro* study conducted years later showing that sodium valproate is a CYP2C9 inhibitor [17]. This pattern of inference is weak since it assumes that the interaction could only occur by means of CYP2C9 inhibition while pharmacology research has exposed other means by which apparent metabolic interactions can occur including inhibition of transport proteins. We could find no studies, such as an *in vitro* assay, designed specifically to examine the whether phenobarbital is metabolized by CYP2C9. Without this missing information, there remains considerable uncertainty behind this assertion.

We identified three major challenges to representing drug mechanism knowledge from this initial experiment. First, there is often considerable uncertainty behind claims about a drug's properties and this uncertainty affects the confidence that someone knowledgeable about drugs places on mechanisms-

based DDI predictions. Another challenge is that mechanism knowledge is sometimes missing; a fact which can make it difficult to assess the validity of some claims about a drug’s mechanisms. Finally, mechanism knowledge is dynamic and any repository for drug mechanism knowledge is faced with the non-trivial task of staying up to date with science’s rapid advances.

### III. RELATED WORK

#### A. Work addressing uncertain mechanism knowledge

Perhaps the most significant challenge we identified is that knowledge about drug mechanisms is often *uncertain*. Our pilot database had no way to represent uncertainty or determine how much confidence one should have in predictions made using uncertain drug facts. There are many methods to support computational reasoning with uncertain knowledge including symbolic methods such as incidence calculus [18], purely numerical approaches such as Bayesian networks [19] and hybrid approaches such as Certainty Factors attached to rules in MYCIN [20] and similar expert system shells. Simon Parsons has written a concise conceptual review of several formalisms [21] as has Peter Norvig [22].

An interesting informatics research project would be to build a drug mechanism knowledge system using one of these methods. In fact various models of drug pharmacokinetics and pharmacodynamics employing some of these methods are being used during early drug development for reasons that include helping to assess the efficacy and safety of new drugs, estimating dose to concentration relationships, and more recently, identifying optimal drug candidates [1]. However, our prior work suggests a more immediate, and perhaps more important research question – what are the strengths and weaknesses of explicitly linking evidence support for drug mechanism assertions and how is evidence support best modelled?

When we looked at other knowledge-based systems that link evidence to their drug facts, including DRUGDEX<sup>2</sup>, Q-DIPS [23], and PharmGKB<sup>3</sup>, we identified limitations to the approaches they use. For example, one limitation of these systems is that they tend to collect evidence only in support of assertions. This bias towards collecting only supporting evidence could undermine attempts to evaluate how believable an assertion is. Psychological studies have shown that people tend to search for evidence that confirm their hypotheses and that this can sometimes lead them to overestimate the likelihood that a hypothesis is true. When subjects were asked to think of situations where their hypotheses would not be true, their confidence estimations were more accurate [24]. The evidence component of the second drug interaction KB that we discuss in Section IV accumulates evidence both for and against object property assertions allowing us to explore the possible benefits and drawbacks of this approach.

Another limitation of the systems we looked at is that they rarely or never provide their criteria for selecting or excluding evidence. The quality of scientific research varies greatly and

busy clinicians and researchers do not have lots of time to evaluate whether the evidence supporting some drug fact meets the proper criteria. A more efficient approach might be for KB maintainer’s to explicitly state the inclusion criteria for every evidence type and ensure that the criteria are met by every piece of evidence they link to drug mechanism assertions. We use this approach to collect evidence for the the second drug interaction KB that we discuss in Section IV.

#### B. Work addressing missing mechanism knowledge

Missing drug mechanism knowledge includes facts that are unavailable or require tests that are impossible or impractical to perform. We found in the pilot study how the absence of studies specifically examining whether phenobarbital is metabolized by CYP2C9 caused the clinical relevance of 11 of the pilot systems DDI predictions to be uncertain. Other examples of missing drug mechanism knowledge are not hard to find; for example, it is well known that certain individuals carry poorly-functioning forms of one or more of the drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP2D6. Knowledge of which form a patient carries can help clinicians plan a drug therapy involving drugs metabolized by one of these enzymes. Unfortunately, it is not practical to genotype every patient so knowledge of whether the patient possesses a mutant enzyme will often be missing.

One way to handle missing knowledge when it is important for reasoning is to assume some truth state for the knowledge until proven otherwise. This is a form of *default reasoning* whose various forms include inheritance in semantic networks, circumscription, default logic, and several advanced methods reviewed by Goldszmidt and Pearl [25]. Implementing default reasoning in a system that performs logical inference requires that the system be *non-monotonic*. Conceptually, this means that the system can retract or reinstate inferences as the belief state of assertions change. Continuing with the example above, a conservative knowledge-based system might, by default, assert that all patients potentially possess the poorly-functioning form of each polymorphic enzyme. The system’s reasoning engine might then make DDI predictions that assume this assertion to be valid. If a clinician decides that their patient carries the normal functioning form of the enzyme then it is feasible for a non-monotonic reasoning system to retract all DDI predictions that depend on the patient having the poorly-functioning enzyme.

One type of non-monotonic logic system is a Justification-based Truth Maintenance System (JTMS) [26]. Typically, a JTMS system works in conjunction with a rule engine to manage assumptions and their effects on inference. We discuss in Section IV how we use a JTMS in our second drug interaction KB; the remainder of this section describes how a JTMS works.

In formal logic, the *antecedent*, or IF portion of an IF-THEN rule, must be true for the *consequent*, or the THEN portion of the rule, to be true. Many rule engines, including our second knowledge-based system, model theories as Horn clauses; rules consisting of one or more clauses forming an *antecedent* and zero or one clauses forming a *consequent*. In

<sup>2</sup><http://www.micromedex.com/products/drugdex/>

<sup>3</sup><http://www.pharmgkb.org/>

traditional predicate calculus, the consequent of a Horn clause is always true if all clauses in its antecedent are true. This is not the case in a system using a JTMS. Rather, a consequent can depend on other clauses in addition to the ones in its antecedent. The set of clauses a consequent depends on is called its *justifications*. In order for a consequent to hold true, all of its justifications must hold true.

The JTMS represents every clause in the rule engine as a node possessing a *label* reflecting its current belief state. Every rule in the rule engine specifies a set of justifications its consequent depends on for belief. The JTMS labels a consequent IN when all of its justifications are IN. If any of a consequent's justifications are OUT, then the consequent is OUT. Justifications can include clauses or *assumptions*. *Assumptions* are clauses that can be IN or OUT by assignment; they do not require any supporting justifications. The JTMS labels an assumption node IN, or *enabled*, when the rule engine *asserts* belief in it, and OUT when the rule engine *retracts* that belief. In this way, the JTMS maintains a dependency network of clauses and justifications. A change in belief in any clause or assumption node recursively propagates through the dependency network, changing the belief state of any other node that contains the changed node in its set of justifications.

### C. Work addressing the dynamic nature of mechanism knowledge

Any repository for drug mechanism knowledge is faced with the non-trivial task of staying up to date with science's rapid advances. Widely used systems like DRUGDEX<sup>®</sup> and Facts and Comparisons<sup>®</sup> use drug product labels as their primary source of drug mechanism knowledge. Unfortunately, drug labels fail to stay up to date with emerging drug mechanism knowledge. For example, since the late 1990s regulatory agencies have recommended detailed investigations into the pharmacokinetic, and especially metabolic, mechanisms during the early stages of a drug's development. However, labeling for older drugs is not current with this emerging knowledge – as of 2002, only 10% of the drugs approved between 1992 and 1997 include *in vitro* metabolic findings and very few labels for drugs approved in the early 1980s even have pharmacokinetic information [27].

A more effective approach is to track and evaluate both drug label and primary research evidence using editorial boards consisting of domain experts. Interestingly, while labeling is the primary source of drug mechanism knowledge for DRUGDEX<sup>®</sup>, Facts and Comparisons<sup>®</sup>, and other comparable systems, these systems use editorial boards to stay current with knowledge from clinical trials or case reports and it has proven scalable to the thousands of drug products listed in these sources. Q-DIPS [23], a system designed to help clinicians identify and manage DDIs that occur by metabolic mechanisms, demonstrates that the editorial board approach is feasible for drug-mechanism knowledge. The system's maintainers curate a database of *in vitro* and *in vivo* studies that support assertions about the enzymes a drug is a substrate of or modulates. Users of Q-DIPS can identify DDIs by viewing tables showing the metabolic properties of the set of drugs they

are interested in. The tables in Q-DIPS are *dynamic* meaning that their content changes as knowledge about each drug's metabolic profile is updated in the study database.

## IV. MODELING WITH EVIDENCE AND TRUTH MAINTENANCE




Fig. 1. A knowledge-based system that links assertions about object properties to the evidence for and against those properties

Building from the lessons of our initial experiment and our review of related work, we have designed a new evidence-based DDI knowledge-base called the *Drug Interaction Knowledge Base*, or DIKB. Figure 1 shows an architectural model of the system. The DIKB enables users to link each assertion about a drug property to both supporting and refuting evidence. DIKB maintainers place evidence for or against each assertion about a drug's mechanistic properties in an *evidence-base* that is kept current through an editorial board approach. Maintainers attach meta-data describing the source and study type of each piece of evidence in the *evidence-base* and users of the system can define specific belief criteria for each assertion in the *evidence-base* using combinations the evidence meta-data.

The system has a separate *knowledge-base* that contains only those assertions in the *evidence-base* that meet belief criteria. The DIKB's reasoning system uses assertions in this *knowledge-base* and so only makes DDI predictions using those facts considered current by the system's maintainers and believable by users. The DIKB uses a JTMS to handle both default reasoning and the effects on inference of changes in the *knowledge-base* as new evidence causes assertions in the *evidence-base* to meet, or fail to meet, belief criteria. To the best of our knowledge, this latter application is a novel use of a JTMS within biomedical informatics.

The DIKB contains the same model for predicting metabolic inhibition interactions validated in our pilot system but only contains assertions about a family of cholesterol lowering drugs called "statins" and drugs that they are sometimes co-prescribed with. While statins have a relatively wide therapeutic index, adverse events, including myopathy and rhabdomyolysis, have been reported due to extreme overexposure [28]. In addition to six statins, the DIKB currently contains knowledge about 11 drugs that are sometimes co-prescribed with statins, have been the subject of numerous pharmacokinetic studies (both *in vivo* and *in vitro*), and are thought to

```
(rule
  (:IN (inhibits ?x ?y))
  (:IN (substrate-of ?z ?y)))
(rassert!
  (inhibit-metabolic-clearance ?x ?z ?y)
  (nil
    (inhibits ?x ?y)
    (substrate-of ?z ?y)
    (inhibitory-concentration ?x ?y)
  )))
```

Fig. 2. A rule in the `ddi-theory` for when a precipitant inhibits the metabolic clearance of an object drug

be substrates or inhibitors of the same enzyme responsible for metabolizing many of the statins (CYP3A4).

The DIKB implements the three modules shown in the Figure 1 using two components; one called the `ddi-theory` and the other called the `evidence-model`. The `ddi-theory` consists of a JTMS, a rule-based theory about DDIs, and assertions about the mechanistic properties of the 17 drugs. The `evidence-model` consists of a database that stores the evidence for and against each assertion in the `ddi-theory` and communicates to the `ddi-theory` which assertions it can use for inference. The `ddi-theory` implements both the *knowledge-base* and the *reasoning system* components of the model in Figure 1. Inference over facts and rules in the `ddi-theory` occurs when a user, or the system, calls an explicit function that executes a forward chaining inference algorithm over the rules and adds any inferred assertions to the *knowledge-base*. At anytime, users can pose queries against the *knowledge-base* and the system will return any assertions about drugs, including drug-drug interaction predictions, that match a user’s query. It will also return links to the evidence for and against each fact used to satisfy the query. We set forth each component of this system in greater detail in the next two sections.

### A. The `ddi-theory`

The `ddi-theory` component of the DIKB consists of two parts – a rule engine and a JTMS that maintains the belief state of clauses in the rule engine. Section III-B relates how a JTMS works, we now show how the JTMS is used in the `ddi-theory` to handle both default reasoning and the effects on inference of changes in the *knowledge-base* as new evidence causes assertions in the *evidence-base* to meet, or fail to meet, belief criteria.

Figure 2 shows a `ddi-theory` rule applicable when a precipitant drug inhibits the metabolic clearance of an object drug. The first line declares that this is a rule, the next line specifies a pattern for when one object inhibits another. The `:IN` before the pattern declares that this clause must be believed in order to evaluate as true. For example, when we assert that clarithromycin (CMYN) inhibits CYP3A4 in the following listing, the JTMS creates a node for the assertion and assigns it an `IN` label.

```
(assert!
  '(inhibits 'CMYN 'CYP3A4)
  'dikb-assertion)
```

The next line in our rule is a clause for when one object is a substrate of another object. To assert that CYP3A4 metabolizes carbamazepine (CARB) we input:

```
(assert!
  '(substrate-of 'CARB 'CYP3A4)
  'dikb-assertion)
```

The consequent in Figure 2 says to assert that `?x` inhibits the metabolic clearance of `?z` by `?y` when the antecedents evaluate true. Then follows a list containing an *informant*, and a series of justifications for the consequent. The *informant* is a variable that further explains the inference; in this case it is set to `nil`. The justifications represent clauses or assumptions that must be `IN` in order for the consequent to be `IN`. When the rule engine makes an assertion, the JTMS creates a node for it and then looks to see if the consequent’s justifications are `IN`. If so, the JTMS labels the node `IN`.

The `ddi-theory` models dynamic and default knowledge as JTMS assumptions. Belief in the truth of dynamic or default information causes the assumption representing that information to be *enabled*. Currently, the DDI theory assumes by default that all precipitants reach a concentration sufficient to cause a clinically significant effect on the enzymes they are known to inhibit. In our example above, the `ddi-theory` would create an enabled assumption declaring CMYN to be at a concentration sufficient to inhibit CYP3A4. The symbol `'default-inference-assumption` is an informant, tracing this assumption to default reasoning.

```
(assume!
  '(inhibitory-concentration 'CMYN 'CYP3A4)
  'default-inference-assumption)
```

Figure 3 shows how the JTMS dependency network would look at this point in our example. If further data causes the belief state of our default assumption to change to false, then the program can retract belief:

```
(retract!
  '(inhibitory-concentration 'CMYN 'CYP3A4)
  'default-inference-assumption)
```

The effect of changing this belief is shown in Figure 4. The JTMS changes the node labels for both the assumption (`inhibitory-concentration 'CMYN 'CYP3A4`) and the assertion (`inhibit-metabolic-clearance CMYN CARB CYP3A4`) to `OUT` meaning that this assertion is no longer believed true. It is important to note that *any other assertions or inferences* that depend directly, or indirectly, on either of these assertions will now also be labeled `OUT`.

Figures 2 and 5 show the rules represented in the




Fig. 3. A small dependency network. Justifications are shown in the box




Fig. 4. A change in the belief state in one of the justifications propagates to dependant consequents

ddi-theory at this time. The rule in Figure 2 and the first rule in Figure 5 capture inhibition of a clearance enzyme of a drug that is primarily cleared by metabolism. The third and fourth rule serve to capture a disjunctive state when a drug has a narrow-therapeutic index and/or is considered a *sensitive substrate*.<sup>4</sup> These rules are necessary because our JTMS implementation can only accept single literal positives and cannot directly assert disjunctive clauses. The final rule in Figure 5 specifies conditions that, if present, greatly increase the likelihood of a clinically significant inhibition interaction.

### B. The evidence-model

The `evidence-model` component of the DIKB stores instances of objects that the `ddi-theory` reasons about, currently limited to drugs. The purpose of the `evidence-model` is to manage knowledge about the properties of the objects it stores and communicate their current state of belief to the `ddi-theory`. Both the set of assertions in `ddi-theory` and their belief state changes as the `evidence-model` accumulates evidence for and against object property assertions. To satisfy its purpose, the `evidence-model`:

- 1) stores evidence for and against each property and its meta-data
- 2) tests the evidence for each property against user-defined criteria for belief
- 3) tells the `ddi-theory` to retract and assert *enabled assumptions* about the properties of its objects

1) *Storing evidence and evidence meta-data*:: The `evidence-model` represents objects of interest to the `ddi-theory` and assertions about their properties as instances of classes derived from an abstract `Frame` class. A simple class, called `KB`, performs storage and retrieval functions for these class instances. This class has two subclasses, or children; `DrugKB` for objects whose properties are

<sup>4</sup>The FDAs defines a sensitive substrate as a substrate that exhibits a 5-fold or greater increase in exposure with the addition of an inhibitor. There are currently several drugs on the FDAs published list including buspirone, eletriptan, felodipine, lovastatin, midazolam, sildenafil, simvastatin and triazolam [6]

```

(rule
  (:IN
    (inhibit-metabolic-clearance ?x ?z ?y)
    :TEST (not (equal ?x ?z))
  ))
(rassert!
  (increase-drug-exposure ?x ?z ?y)
  (nil
    ;; justifications
    (inhibit-metabolic-clearance ?x ?z ?y)
    (primary-clearance-mechanism
      ?z 'METABOLISM)
  )))

(rule
  (:IN (narrow-therapeutic-range ?z)))
(rassert!
  (nti-or-sensitive-substrate ?z)
  ;; justifications
  (nil
    (narrow-therapeutic-range ?z)
  ))

(rule
  (:IN (sensitive-substrate ?z)))
(rassert!
  (nti-or-sensitive-substrate ?z)
  ;; justifications
  (nil
    (sensitive-substrate ?z)
  ))

(rule
  (:IN (increase-drug-exposure ?x ?z ?y))
  (:IN (primary-clearance-enzyme ?z ?y))
  (:IN (nti-or-sensitive-substrate ?z)))
(rassert!
  (metabolic-inhibition-interaction ?x ?z ?y)
  ;; justifications
  (nil
    (increase-drug-exposure ?x ?z ?y)
    (primary-clearance-enzyme ?z ?y)
    (nti-or-sensitive-substrate ?z)
  )))
  
```

Fig. 5. The DDI theory consists of these rules plus the one shown in Figure 2

important for inference and `EvidenceBase` for assertions about the properties of these objects.

As of this writing, the singleton `DrugKB` only contains instances of type `Drug`, a class that models knowledge about a drug and its properties (Table II). The class `Drug` contains two types of slots, *categorical* slots that store plainly factual knowledge about a drug such as its generic and trade names and *evidence* slots that model knowledge about a drug property that rests on conclusions from research. The singleton `EvidenceBase` stores instances of class `Assertion` (Table III); a class that models the evidence both for and against an property belonging to some instance in `DrugKB`. When users find evidence for or against the property represented by an *evidence* slot they create a new instance of the `Evidence` class shown in Table IV and enter values for its slots. These instances are then placed in either the *evidence-for* or *evidence-against* slot of the `Assertion` instance as-

TABLE II

THE CURRENT MODEL FOR DRUG OBJECTS. THE CLASS DRUG CONTAINS TWO TYPES OF SLOTS, *categorical* SLOTS THAT STORE PLAINLY FACTUAL KNOWLEDGE ABOUT A DRUG SUCH AS ITS GENERIC AND TRADE NAMES AND *evidence* SLOTS THAT MODEL KNOWLEDGE THAT RESTS ON CONCLUSIONS FROM RESEARCH.

Slot	Type	Description
generic-name	<i>categorical</i>	FDA generic name
trade-name	<i>categorical</i>	manufacturer's name
drug-class	<i>categorical</i>	therapeutic class of the drug
form	<i>categorical</i>	default form of administration
ingredients	<i>categorical</i>	active and inactive ingredients
prodrug	<i>categorical</i>	is the drug a prodrug? true or false
substrate-of	<i>evidence</i>	enzymes that metabolize this drug
inhibits	<i>evidence</i>	enzymes this drug inhibits
induces	<i>evidence</i>	enzymes this drug induces
level-of-first-pass	<i>evidence</i>	level of first pass metabolism
primary-clearance-enzyme	<i>evidence</i>	the enzyme that accounts for the greatest amount of metabolic clearance
primary-clearance-mechanism	<i>evidence</i>	primary route clearance - metabolism, renal or exhalation
narrow-therapeutic-index	<i>evidence</i>	does the drug have a narrow therapeutic range - true or false
sensitive-substrate	<i>evidence</i>	enzymes for which this drug meets the FDA's definition of a sensitive substrate

sociated with the property's *evidence* slot.

TABLE III  
SLOTS IN CLASS ASSERTION

Slot	Description
object	the object's name in DrugKB
slot	name of the slot
value	an allowable value for this slot
evidence-for	a list of Evidence types
evidence-against	a list of Evidence types
ready-to-classify	True if this assertion is ready to classify
evidence-rating	The current classification state of the assertion

TABLE IV  
SLOTS IN CLASS EVIDENCE

Slot	Description
evidence-type	a meta-data label describing the evidence's type (Table V)
doc-pointer	a pointer to the evidence document
quote	a short summary of the evidence
reviewer	person entering this evidence

2) *User-defined criteria for belief and disbelief*:: We relate in our description of pilot work (Section II) how we looked at evidence support for the facts in the pilot database to assess the validity of the system's predictions. The reader might recall that when we looked at the evidence support for zafirlukast inhibition of CYP3A4 and gemfibrozil inhibition CYP2C9 were able to say that the clinical relevance of the interaction prediction involving zafirlukast was less certain than the two interactions involving gemfibrozil inhibition of CYP2C9. This case and others from our early work suggest that the confidence someone knowledgeable about drugs has in the clinical validity of a DDI prediction varies with depending on the *type* of evidence that support or refute each of the facts that led to the prediction. To explore this idea further, the DIKB supports using evidence types to track the level of certainty users have

in the system's drug mechanism assertions.

The types of evidence that can support drug mechanism facts include, among others, labeling statements, results from *in vitro* studies, expert interpretation of case reports, and various pharmacokinetic trials involving volunteers. A novel feature of the DIKB is that expert users can define combinations of evidence that they believe lend different degrees of certainty to the assertion types that the DIKB uses to predict DDIs. Different combinations of evidence types might confer different levels of certainty in an assertion and these can be rank ordered to produce "levels of evidence" (LOEs).

The DIKB distinguishes between assertion *instances* and assertion *types*. An assertion instance is a specific fact about a particular object such as a drug or protein. For example, (substrate-of 'CARB 'CYP3A4) is an instance of the generic (substrate-of X Y) assertion type. DIKB users define one or more LOEs for each generic assertion type by creating logical statements listing the level's required evidence types and their multiplicity. The LOEs for an assertion type apply to any instance of that type. Users can also place evidence types that they feel have similar levels of validity into a group called a *ranking category*. They can then use the ranking category just like other evidence types to define LOEs.

For every assertion type users select one LOE as the *belief criteria*. The evidence-model will tell the ddi-theory to use a particular assertion instance in inference if, and only if, there exists a body of evidence for the assertion that satisfies the *belief criteria* for the assertion's type and there is no evidence against the object property. Table V show some of the evidence-types and ranking categories we are currently experimenting with and Figure 6 shows some example LOEs.

3) *Asserting and retracting enabled assumptions*:: There are two situations where the evidence-model will re-assess the evidence for an assertion about one of its objects – when an assertion's evidence support changes or DIKB users change the LOE that they have selected as the belief criteria for the assertion's type. In either case, the evidence-model compares the evidence for and against the assertion. If the

TABLE V

A SET OF EVIDENCE TYPES THAT WE ARE EXPERIMENTING WITH ORGANIZED BY AN EXPERIMENTAL RANKING SCHEME. USERS ASSIGN ONE OF THESE EVIDENCE TYPES TO EACH ITEM THEY ENTER INTO DIKB.

<i>Ranking Category</i>	<i>Evidence Type</i>
• <b>RCT</b>	<ul style="list-style-type: none"> <li>• a randomized, controlled, pharmacokinetic study</li> </ul>
• <b>Non-random</b>	<ul style="list-style-type: none"> <li>• a cohort study</li> <li>• a case-control study</li> <li>• a non-randomized trial with concurrent or historical controls</li> <li>• a retrospective study looking a clinical records over time</li> <li>• a fixed order study with non-randomized healthy volunteers</li> </ul>
• <b>Case Reports</b>	<ul style="list-style-type: none"> <li>• a single case report</li> <li>• a case series</li> </ul>
• <b>FDA Guidances</b>	<ul style="list-style-type: none"> <li>• a statement in an FDA guidance to industry</li> </ul>
• <i>in vitro</i>	<ul style="list-style-type: none"> <li>• <i>in vitro</i> evidence from human tissue, micro-somal</li> <li>• <i>in vitro</i> evidence from human tissue, recombinant</li> </ul>
• <b>Drug Labeling</b>	<ul style="list-style-type: none"> <li>• Non-cited information in a drug label</li> <li>• Non-cited <i>in vitro</i> information in a drug label</li> <li>• Non-cited <i>in vivo</i> information in a drug label</li> </ul>

```

LOE-1 ::= RCT+ |
          FDA Guidances+
LOE-2 ::= LOE-1 |
          Drug Labeling+
LOE-3 ::= LOE-2 |
          Drug Labeling+ |
          (in vitro+ and Non-random+)
LOE-4 ::= LOE-2 |
          in vitro+ |
          Non-random+

```

Fig. 6. A set of levels of evidence (LOE) we are testing. The symbol ‘::=’ means the term to the left “is defined as” the term to the right, ‘|’ means “or”, and ‘+’ means that “one or more occurrences of” of the symbol to the left are allowed. So item one reads “LOE-1 is defined as one or more **RCT** OR one or more **FDA Guidance** evidence types.”

evidence for the assertion satisfies the belief criteria currently assigned to the assertion’s type, and there is no evidence against the assertion, then the `evidence-model` will cause the assertion to be enabled (labeled IN) in the `ddi-theory`. The `evidence-model` will retract (label OUT) the same assertion when either 1) evidence against the assertion is found or 2) the belief criteria changes and the evidence for an assertion is no longer sufficient. Since object properties might already be asserted or retracted in the `ddi-theory`, the `evidence-model` keeps track of state. For example, if the `evidence-model` has already enabled an assertion and the assertion’s evidence continues to meet belief criteria, then the system will make no change.

## V. IMPLEMENTATION AND EXAMPLES

Users can enter and view evidence for drug property assertions into the `evidence-model` from a web interface. This same interface allows users to select belief criteria and re-assess evidence. Both the web interface and the `evidence-model` are implemented in Python.<sup>5</sup> The latter is implemented as a set of Python classes and shell scripts while the former uses the HTMLGen library<sup>6</sup> for creating web pages and the Twisted networking framework<sup>7</sup> for serving them.

The `ddi-theory` uses Forbus and De Kleer’s ANSI Common Lisp rule engine (JTRE) and JTMS from [26] with no modification. The rules shown Figures 2 and 5 are enclosed in a Lisp function that initializes globally accessible JTRE and JTMS objects. The `evidence-model` writes asserted and retracted assumptions to a file stored on disk. This file is manually loaded by the user from an interactive Lisp session each time the `evidence-model` re-assesses its evidence.

Table VI shows the output of our system using the rules in Figures 2 and 5, a subset of the drug properties and evidence in `evidence-model`, and three of the levels of evidence shown in Figure 6. The table illustrates one advantage of using evidence meta-data to specify belief criteria for assertions in the knowledge-base – the system can provide different

<sup>5</sup><http://www.python.org>

<sup>6</sup><http://starship.python.net/crew/friedrich/HTMLgen/html/main.html>

<sup>7</sup><http://twistedmatrix.com/>

views of its knowledge and inferences to users who might not agree about what combination of evidence makes an assertion believable. LOE-1 accepts only one or more evidence items from either the **RCT** or **FDA Guidance** categories as evidence. LOE-2 adds to this the a very significant source of evidence; **labeling**. As is shown, changing the level of evidence from LOE-1 to LOE-2 has a dramatic effect on the belief state of predicted DDIs. Only one change in predicted DDIs occurs when moving from LOE-2 to LOE-4; the prediction that fluvastatin will inhibit the metabolic clearance of rosuvastatin. This is because, *at the time of this writing*, evidence-model contains only one item of evidence for the claim that fluvastatin inhibits CYP2C9; an *in vitro* type acceptable only at LOE-4.

Table VII demonstrates how the DIKB output changes when maintainers find new evidence that causes an assertion in the *evidence-base* to meet a belief criteria where it did not before. As the table shows, the hypothetical addition of an item of **RCT** evidence that fluvastatin inhibits CYP2C9 would cause the system's prediction that fluvastatin will inhibit the metabolic clearance of rosuvastatin via CYP2C9 to be believed at *LOE-2*. It is important to note that *any other assertions or inferences* that depend directly, or indirectly, on this inference will now also be labeled **IN** provided that all of their other justification are **IN**. This example shows how a JTMS can efficiently handle the effects on inference of changes the *knowledge-base* as new evidence causes assertions in the *evidence-base* to meet, or fail to meet, a user's belief criteria.

## VI. DISCUSSION

The DIKB implements our proposed methods for handling absent, uncertain, and and changing drug mechanism knowledge. We are now beginning to use the system to explore the strengths and limitations of our proposed methods including the DIKB's novel use of a Truth Maintenance System to link changes in the evidence support for assertions about drug properties to the set of drug-drug interactions and non-interactions the system predicts. This section relates some observations and lessons we have learned from implementing the system.

### A. The DIKB as an system for research

The DIKB's reasoning system, like that of our prototype system, is unable to track uncertainty through inference. Rather, the DIKB automatically selects assertions that meet user defined belief criteria assuming that these assertions are certain from the user's perspective. If the user selects belief criteria that represent full confidence in each assertion type, and each assertion the DIKB uses meets the user's belief criteria then, so will its DDI predictions. This arrangement is useful for researching how evidence can be used to establish the certainty of drug mechanism knowledge but it does not address how to handle assertions that do not meet belief criteria.

The DIKB does not prevent users from assigning as belief criteria LOEs that do not inspire their full confidence in an

assertion. However, the system has no way of establishing the certainty a user should have in a DDI prediction that depends on such assertions. One can imagine scenarios where having knowledge of even uncertain DDI predictions could be valuable. For example, if the perceived risk of death to a patient is high, a clinician might want to be extra cautious while determining a drug therapy and avoid, if possible, every predicted DDI, regardless of the certainty of its occurrence. In such cases, selecting as belief criteria an LOE that does confer complete confidence in an assertion might be justified if it had the effect of producing more, though possibly less certain, DDI predictions. It might be possible to assign a numerical value to each LOE that represents the user's certainty in any assertion possessing the combination of evidence the LOE models. Then, the system could arrive at a final certainty value for any inference by combining the confidence value for all the assertions it depends on using some theory of reasoning under uncertainty. We are currently designing experiments that will explore the feasibility of this treatment of LOEs by testing the accuracy of the DIKB using many different combinations of belief criteria.

### B. Ensuring the quality of evidence

The DIKB assumes that it is possible to map a user's confidence in an assertion type to some arrangement of one or more abstract evidence types. Belief criteria are established based on a prospective arrangement of evidence meta-data rather than a specific review of evidence items. Unfortunately, there are many possible problems with studies or other types of evidence that can affect their quality. A poor quality study could provide false support for an assertion so we need some way to tell users in advance what the quality of an item will be.

To address this issue, we are developing inclusion criteria for each type of evidence in the DIKB. Our inclusion criteria are explicit conditions that each type of evidence must meet to be used in the DIKB. For example, we define a quality pharmacokinetic study as one where the duration and magnitude of dosing is adequate for the drugs involved, patient genotype is noted if target enzyme is polymorphic, and, if drug has active metabolites, the duration and magnitude of dosing is adequate to account for their effect on the enzyme pool. Similarly, we define quality labeling information as an unambiguous statement from the most currently available label source. We are defining inclusion criteria for each type of evidence and being careful to only enter evidence into the system that satisfies our inclusion criteria.

### C. Incorporating assumptions can help maintain the system's knowledge:

One significant finding from implementing the DIKB is that incorporating assumptions into the evidence model can facilitate keeping knowledge in the system current. In building the DIKB we noticed that interpreting the results of a scientific investigation as support for a particular assertion can sometimes require making assumptions that scientific advance might later prove to be invalid. When assumptions are later

TABLE VI

THE BELIEF STATE OF A SUBSET OF DRUG PROPERTY ASSERTIONS AND INFERENCES IN THE DIKB WHEN THREE DIFFERENT LEVELS OF EVIDENCE FROM FIGURE 6 WERE CHOSEN AS BELIEF CRITERIA. INFERENCES WERE MADE USING THE RULES IN FIGURES 2 AND 5. THE EVIDENCE FOR EACH DRUG PROPERTY IS SHOWN; NO DRUG PROPERTY SHOWN HAD EVIDENCE *against* IT.

Drug property assertions				
Drug Property	Evidence for	LOE-1	LOE-2	LOE-4
(INHIBITS 'DILTIAZEM 'CYP3A4)	RCT, Non-random, <i>in vitro</i>	IN	IN	IN
(INHIBITS 'FLUVASTATIN 'CYP2C9)	<i>in vitro</i>	OUT	OUT	IN
(SUBSTRATE-OF 'SIMVASTATIN 'CYP3A4)	RCT, Non-random, <i>in vitro</i>	IN	IN	IN
(SUBSTRATE-OF 'ROSUVASTATIN 'CYP2C9)	label	OUT	IN	IN
(PRIMARY-CLEARANCE-ENZYME 'SIMVASTATIN 'CYP3A4)	label	OUT	IN	IN
(PRIMARY-CLEARANCE-MECHANISM 'SIMVASTATIN 'METABOLISM)	label	OUT	IN	IN
(SENSITIVE-SUBSTRATE 'SIMVASTATIN 'CYP3A4)	FDA Guidance	IN	IN	IN

Predicted Drug-drug interactions				
Drug Property		LOE-1	LOE-2	LOE-4
(INHIBIT-METABOLIC-CLEARANCE 'DILTIAZEM 'SIMVASTATIN 'CYP3A4)		OUT	IN	IN
(INCREASE-DRUG-EXPOSURE 'DILTIAZEM 'SIMVASTATIN 'CYP3A4)		OUT	IN	IN
(METABOLIC-INHIBITION-INTERACTION 'DILTIAZEM 'SIMVASTATIN 'CYP3A4)		OUT	IN	IN
(INHIBIT-METABOLIC-CLEARANCE 'FLUVASTATIN 'ROSUVASTATIN 'CYP2C9)		OUT	OUT	IN
(INCREASE-DRUG-EXPOSURE 'FLUVASTATIN 'ROSUVASTATIN 'CYP2C9)		OUT	OUT	OUT

TABLE VII

A HYPOTHETICAL EXAMPLE SHOWING HOW THE ADDITION OF NEW EVIDENCE TO THE DIKB CAN EFFECT A CHANGE IN WHICH PREDICTIONS ARE CONSIDERED BELIEVABLE DEPENDING ON THE LOE SELECTED AS BELIEF CRITERIA. HERE, AN RCT TYPE SUPPORTING (INHIBITS 'FLUVASTATIN 'CYP2C9) HAS BEEN ADDED CAUSING ONE OF THE SYSTEM'S INFERENCES TO BE BELIEVED AT LOE-2. †– ITEMS DIFFERENT FROM TABLE VI.

Drug property assertions				
Drug Property	Evidence for	LOE-1	LOE-2	LOE-4
(INHIBITS 'FLUVASTATIN 'CYP2C9)	<i>in vitro</i> , RCT†	IN	IN†	IN
(SUBSTRATE-OF 'ROSUVASTATIN 'CYP2C9)	label	OUT	IN	IN

Predicted Drug-drug interactions				
Drug Property		LOE-1	LOE-2	LOE-4
(INHIBIT-METABOLIC-CLEARANCE 'FLUVASTATIN 'ROSUVASTATIN 'CYP2C9)		OUT	IN†	IN

shown to be false, it is important to re-consider how much support the original investigation lends to any assertion it was once thought to support.

For example, assume that we find a pharmacokinetic study involving healthy patients that shows a significant increase in patient exposure to simvastatin in the presence of diltiazem. If the study meets our inclusion criteria, and if we have knowledge that simvastatin is primarily cleared by CYP3A4, we might apply this evidence as support for the the assertion (*diltiazem inhibits CYP3A4*). Since our use of diltiazem-simvastatin study as supporting evidence for the assertion (*diltiazem inhibits CYP3A4*) depends on the assumption that simvastatin is primarily cleared by CYP3A4, we would want to reconsider using this evidence if future work reveals that simvastatin is not primarily cleared by CYP3A4 or that diltiazem increases patient exposure to simvastatin by some other mechanism (e.g. transport protein modulation).

Unlike systems that just cite evidence, a formal model of evidence like the DIKB's *evidence-model* can help flag when an assumption has become invalid and alert maintainers to the need to reassess their original interpretation of what facts a piece of evidence supports. With some simple modifications,

the DIKB could inform maintainers that a piece of evidence supporting an assertion should be reassessed if 1) users make the assumption known to the DIKB by adding it as a new assertion in the the *evidence-model* and linking it to any use of evidence that depends on the assumption and 2) we program the DIKB to alert users if there is a change in the belief state of any assumption in the system. This functionality is possible by a small change to the system that we will make in future work.

#### D. Expanding the DIKB

An important concern is how feasible it would be to expand the system's DDI prediction ability to more drugs and mechanisms. New drugs can be easily added to the system but each addition increases the number of assertions for which system maintainers need to collect evidence for. Adding more mechanisms is more difficult since it requires that we develop and validate new DDI prediction rules. Rules can come from many sources including experts in pharmacology and textbooks (e.g. [29]). Once the new rules are developed, they can be added to the reasoning system along with any new object properties that the rules require. Maintainers may then begin to collect evidence for the new properties; this might

require developing new evidence types, levels-of-evidence, and belief criteria. In both cases, a major limiting factor is the amount of knowledge that the editorial process can keep up to date. We will collect more data on this issue as we experiment with the system.

## VII. CONCLUSIONS

This paper describes a working system that links drug property assertions to their supporting evidence and allows users to define and vary the criteria for belief in an assertion. In comparison with other knowledge-based systems that link evidence to their drug facts the DIKB is unique in that 1) it collects evidence both for and against assertions, 2) it uses explicitly stated inclusion criteria, 3) it enables users to define levels of evidence and belief criteria for assertions using evidence meta-data, and 4) it can provide different views of its knowledge and inferences to users who might not agree about what combination of evidence makes an assertion believable.

We anticipate that this research could lead to improvements in patient safety by suggesting improvements to the methods commercial drug interaction knowledge-bases use to represent drug mechanism knowledge and its evidence. Our research could also have broad informatics implications outside of modeling drug interactions. For example, the pathway/genome databases in MetaCyc<sup>8</sup> link evidence meta-data to many of their assertions [30] but cannot use these evidence meta-data to provide different views of its knowledge and inferences to users who might not agree about what combination of evidence makes an assertion believable.

The design of the DIKB addresses several of the issues with modeling drug mechanism knowledge. More research is necessary to determine the strengths and limitation of linking evidence to facts in a DDI knowledge-base and to validate the use of evidence meta-data to define belief criteria for drug mechanism facts. For future work we will 1) ensure that all evidence in the system is current and use the system to predict all metabolic drug-drug interactions and non-interactions for the 17 drugs in the system, 2) Validate the use of evidence meta-data to assign a subjective assessment of the degree of certainty for drug mechanism facts by compiling all known metabolic inhibition interactions and non-interactions between the 17 drugs and the testing the accuracy of DDI predictions using various, representative, belief criteria.

## ACKNOWLEDGEMENT

Fellow student Brenton Louie helped with data entry for the pilot drug knowledge-base and later with the online searches used to validate predictions. The authors thank the anonymous reviewers of this article and Dr. Tom Hazlet for their helpful comments and suggestions.

## REFERENCES

- [1] H. Derendorf, L. Lesko, P. Chaikin, W. Colburn, P. Lee, R. Miller, R. Powell, G. Rhodes, D. Stanski, and J. Venitz, "Pharmacokinetic/pharmacodynamic modeling in drug research and development," *J Clin Pharmacol*, vol. 40, pp. 1399–1418, 2000.
- [2] F. Yamashita and M. Hashida, "In silico approaches for predicting ADME properties of drugs," *Drug Metab Pharmacokin*, vol. 19, no. 5, pp. 327–338, 2004.
- [3] H. van de Waterbeemd and E. Gifford, "ADMET in silico modlling: towards prediction paradise," *Nature Reviews*, vol. 2, pp. 192–204, March 2003.
- [4] R. S. Obach, R. L. Walsky, K. Venkatakrishnan, J. B. Houston, and L. Tremaine, "In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach," *Clin Pharmacol Ther*, vol. 78, pp. 582–92, 2005.
- [5] P. Hansten, "Drug interaction management," *Pharmacy World and Science*, vol. 25, no. 3, Jun 2003.
- [6] Internal, "FDA guideline: Drug interaction studies – study design, data analysis, and implications for dosing and labeling," Internet, September 2006, draft. Last accessed 09/25/2006.
- [7] P. D. Hansten and J. R. Horn, *The Top 100 Drug Interactions, A Guide to Patient Management*. H&H Publications, 2004, ch. Cytochrome P450 Enzymes and Drug Interactions.
- [8] C. Collins and R. Levy, "Drug-drug interaction in the elderly with epilepsy: Focus on antiepileptic, psychiatric, and cardiovascular drugs," *Profiles in Seizure Management*, vol. 3, no. 6, 2004.
- [9] R. Boyce, C. Collins, J. Horn, and I. Kalet, "Qualitative pharmacokinetic modeling of drugs," in *Proceedings of the AMIA*, 2005, pp. 71–75.
- [10] AstraZeneca, "Accolate<sup>®</sup> zafirlukast tablets," July 2004, product label.
- [11] J. H. Lin, "Sense and nonsense in the prediction of drug-drug interactions," *Current Drug Metabolism*, vol. 1, no. 4, pp. 305–332, 2000.
- [12] K. Ito, H. S. Brown, and J. B. Houston, "Database analysis for the prediction of in vivo drug drug interactions from in vitro data," *British Journal of Clinical Pharmacology*, vol. 57, no. 4, pp. 473–486, 2003.
- [13] X. Wen, J. Wang, J. Backman, K. Kivisto, and P. Neuvonen, "Gemfibrozil is a potent inhibitor of human cytochrome P4502C9," *Drug Metab Dispos.*, vol. 29, no. 11, pp. 1359–61, Nov 2001.
- [14] J. Rindone and H. Keng, "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia," *Chest*, vol. 114, no. 2, pp. 641–2, Aug 1998.
- [15] I. Kapetanovic and H. Kupferberg, "Stable isotope methodology and gas chromatography mass spectrometry in a pharmacokinetic study of phenobarbital," *Biomed Mass Spectrom*, vol. 7, no. 2, pp. 47–52, 1980.
- [16] I. Kapetanovic, H. Kupferberg, R. Porter, W. Theodore, E. Schulman, and J. Penry, "Mechanism of valproate-phenobarbital interaction in epileptic patients," *Clin Pharmacol Ther*, vol. 29, no. 4, pp. 480–6, Apr 1981.
- [17] X. Wen, J. Wang, K. Kivisto, P. Neuvonen, and J. Backman, "In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)," *Br J Clin Pharmacol.*, vol. 52, no. 5, pp. 547–53, 2001.
- [18] A. Bundy, "Incidence Calculus," University of Edinburgh, 80 South Bridge, Edinburgh Eh1 1HN, Scotland, DAI research paper, April 2004, commissioned by the Encyclopedia of Artificial Intelligence.
- [19] J. Pearl and S. Russell, "Bayesian networks," UCLA Cognitive Systems Laboratory, Tech. Rep., November 2000.
- [20] R. Davis, B. Buchanan, and E. Shortliffe, "Production rules as a basis for a knowledge-based consultation program," *Artificial Intelligence*, vol. 8, no. 1, pp. 15–45, 1977.
- [21] S. Parsons and A. Hunter, "A review of uncertainty handling formalisms," in *Applications of Uncertainty Formalisms*, 1998, pp. 8–37. [Online]. Available: citeseer.ist.psu.edu/parsons98review.html
- [22] S. Russel and P. Norvig, *Artificial Intelligence: a Modern Approach*. Prentice Hall, 2003, ch. Probabilistic reasoning.
- [23] P. Bonnabry, J. Sievering, T. Leemann, and P. Dayer, "Quantitative Drug Interactions Prediction System (Q-DIPS): A Dynamic Computer-Based Method to Assist in the Choice of Clinically Relevant In Vivo Studies," *Clinical Pharmacokinetics*, vol. 40, no. 9, pp. 631–640, 2001.
- [24] D. Griffin and L. Brenner, *The Blackwell Handbook of Judgement and Decision Making*. Blackwell, 2004, ch. Perspectives On Probability Judgment.
- [25] M. Goldszmidt and J. Pearl, "Qualitative probabilities for default reasoning, belief revision, and causal modeling," *Artificial Intelligence*, no. 84, pp. 57–112, 1996.
- [26] K. D. Forbus and J. D. Kleer, *Building Problem Solvers*. MIT Press, 1993.
- [27] P. Marroum and J. Gobburu, "The product label: how pharmacokinetics and pharmacodynamics reach the prescriber," *Clin Pharmacokin.*, vol. 41, no. 3, pp. 161–9, 2002.

<sup>8</sup><http://metacyc.org/>

- [28] D. Williams and J. Feely, "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors," *Clin Pharmacokinetics*, vol. 41, no. 5, pp. 343–370, 2002.
- [29] R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hansten, and M. Eichelbaum, Eds., *Metabolic Drug Interactions - Kenneth E. Thummel and Kent L. Kunze and Danny D. Shen*. Lippincott, Williams, and Wilkins, 2000, ch. Metabolically-Based Drug-Drug Interactions: Principles and Mechanisms.
- [30] P. Karp, S. Paley, C. Krieger, and P. Zhang, "An evidence ontology for use in pathway/genome databases," in *Pacific Symposium on Biocomputing 2004*, 2004, pp. 190–201.

**Ira Kalet** received the B.A. degree in physics from Cornell University in 1965 and the Ph.D. degree in theoretical physics from Princeton University in 1968. His dissertation was on "Low Energy Theorems for Meson Production by Real and Virtual Photons". He held research and faculty appointments at the University of Washington Physics Department, the Robert Hutchins School of Liberal Studies at Sonoma State College, and the Graduate School of Education at the University of Pennsylvania before coming to the University of Washington in 1978 in the then newly formed Department of Radiation Oncology.

He is currently a Full Professor in the department of Medical Education and Biomedical Informatics and the department of Radiation Oncology as well as an Adjunct Professor in the departments of Bioengineering, Computer Science and Engineering, and the department of Biological Structure at the University of Washington.

**Richard D. Boyce** received the B.S. degree in computer science from Central Washington University in 2003 and the M.S. in biomedical and health Informatics from the University of Washington, Seattle, in 2005.

He is currently a Ph.D candidate in biomedical and health informatics at the University of Washington. The focus of his dissertation is on representing drug mechanism knowledge to support predicting clinically relevant drug-drug interactions. He was a National Library of Medicine pre-doctoral research fellow from 2003 to 2006 and currently is a research associate in the Department of Pathobiology at the University of Washington and a part-time analyst at the Fred Hutchinson Cancer Research Center, Seattle. His research interests include biomedical knowledge-representation, biomedical decision support, and bioinformatics.

**Carol Collins** received the BS degree in agriculture, the MS in physiology and the MD at the Ohio State University (1991).

After completing a residency in urology, she worked in clinical practice and clinical research. Currently she is a Senior Research Scientist in the Department of Pharmaceutics at the University of Washington. Her research interests include translation of pharmaceutical research into clinical decision making tools and personalized medicine.

**John Horn** received his Bachelor of Pharmacy degree from Washington State University, Pullman, Washington. He completed a Clinical Pharmacy residency at Deaconess Hospital in Spokane, Washington and obtained his Doctor of Pharmacy degree at the University of Cincinnati, Cincinnati, Ohio.

He is a Professor of Pharmacy, Department of Pharmacy at the University of Washington School of Pharmacy and an Associate Director of the University of Washington Medical Center Pharmacy Services. He has authored nearly 100 articles related to drug interactions. He is co-author of *The Top 100 Drug Interactions; A Guide to Patient Management*, Freeland Washington: H&H Publications, LLP, 2007, a pocket-sized book of common drug interactions that is in its 8th edition. Dr. Horn is also co-authored of the reference text *Hansten and Horn's Drug Interactions Analysis and Management*, St. Louis, Missouri: Wolters Kluwer Health, 2007 that is updated every three months and is recognized as the standard reference on drug interactions. These references have been translated into 5 languages and distributed to health care practitioners world-wide.

Dr. Horn is one of the founders of the Drug Interaction Foundation that has developed standardized methods of evaluating potential drug interactions and outcome-based criteria for rating the potential significance of drug interactions. He is a Fellow of the American College of Clinical Pharmacy and a member of the American Society of Health-Systems Pharmacists. He is currently Chair of the Drug Interactions Specialty Panel for *The Annals of Pharmacotherapy*, a member of the editorial board of *Pharmacotherapy*, and serves as a reviewer for several medical and pharmaceutical journals.